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a b s t r a c t
Myasthenia gravis is a disease of neuromuscular junction due to auto-immune destruction
of the acetylcholine receptors. Behçet's disease, on the other hand, is a multisystemic
vascular-inﬂammatory disease. Both conditions are not common in the general population
although their association has not been reported in the literature. We wanted to present our
patient who developed clinical course of myasthenia gravis following discontinuation of
medications due to complications of corticosteroid for Behçet's disease. It was observed that
clinical ﬁndings of myasthenia gravis recovered following restarting steroid treatment
and he did not experience attacks of both conditions. Although Myasthenia gravis and
Behçet's disease are distinct entities clinically as well as in terms of pathogenesis, they
share common physiopathological features and their treatment is based on their common
features.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Myasthenia gravis (MG) is a disease of muscles developing as a
consequence of autoimmune destruction of nicotinic acetylcho-
line receptors [1]. It is characterized by muscle weakness
manifesting with ophthalmoplegia, ptosis, and repetitive move-
ments [2]. It is usually associated with other autoimmune
conditions such as rheumatoid arthritis, hyperthyroidism, and* Corresponding author at: Department of Neurology, Celal Bayar Univ
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are often used and corticosteroids, plasmapheresis, and immune
suppressive agents, and thymectomy in severe cases [3].
Behçet's disease (BD) is a chronic vascular-inﬂammatory
disease of unknown pathogenesis presenting with mucocuta-
neous lesions, attacks of uveitis that may lead to blindness,
involvement that may be fatal of many organs and systems
including nervous, vascular, musculo-skeletal, and gastroin-
testinal systems. According to the new criteria the ocularersity, 45000 Manisa, Turkey. Tel.: +90 5362566809.
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neurological ﬁndings, vascular ﬁndings, and the pathergy test
are evaluated. The skin lesions and neurological and vascular
ﬁndings are each given one point while others are given
2 points. The pathergy test is optional and given one point.
Total score is estimated from the points given to each criterion
and 4 or higher scores are considered as Behçet's disease [4].
A strong association has been found between positivity of
HLA-B51 and prevalence of the disease [5,6]. BD is referred as
Neurobehcet Disease (NBD) if it is associated with involvement
of the CNS [7].
The subject presented here had clinical course of MG
occurring after discontinuing the medication due to complica-
tions of the corticosteroids in a male patient who had been
using prednisolone for 17 years without interruption due to
diagnosis of BD. We did not ﬁnd any data in the literature on
association of both conditions.
2. Case report
A 42 years old man presented to outpatient clinic of Neurology
Department of Medical Faculty of University with speech
disorder, disphagia, and nasal regurgitation of food.
In March of 2014, the patient had been scheduled to have
operation in orthopedics clinic in a state hospital for rupture of
tendon of Achilles and his treatment with prednisolone and
azathioprine had been discontinued. Findings of myasthenia
gravis with bulbar involvement were observed 5 days after the
medication had been discontinued. Thus, the patient was
admitted to our clinic. The patient developed speech disorder,
dysphagia, and ptosis. The otolaryngologist whom the patient
had visited for complaint of dysphagia started antibiotic
treatment with Ampicillin but complaints of the patient
increased despite antibiotic treatment. The subject was
admitted to our clinic with presumed diagnosis of Behçet's
disease – Neuromuscular disease.
History of the patient revealed that the patient was
diagnosed as having BD in an outer center that he presented
with oral and genital aphtas and 2 attacks of uveitis in 1998
and then he was started treatment with colchicine. The
patient reported that he did not experience attacks of oral or
genital aphthas and uveitis 15 years after treatment with
prednisolone at dose of 8 mg/day and azathiopyrine 150 mg/
day. Pathergy test was positive.
On physical examination, the patient had no skin lesion,
arterial pulsations were palpable on both lower and upper
limbs, and there were no signs of venous insufﬁciency. On
auscultation, cardiac sounds were rhythmic and pulmonary
sounds were normal. No organomegaly was found on
abdominal examination.
On the neurological examination; minimal restriction in
bilateral conjugated and upward gaze (ranging between 15 and
30 degrees). There was ptosis on the left lid. Ptosis worsened
and gaze restriction increased with fatigue test. Ptosis
markedly improved with ice test. Eye closing was bilaterally
weak, muscle strength of the neck ﬂexors was 4/5, speech was
moderately nasal in character, and gag reﬂex was bilaterally
absent. There was no another signiﬁcant ﬁnding on neurolog-
ical examination.Routine biochemical investigations (fasting blood glucose,
hepatic function tests, renal function tests, muscle enzymes,
and electrolytes), hemogram, complete urine analysis, vitamin
B12, folic acid, thyroid function tests, and sedimentation rate
were all within normal limits.
Thoracic CT and whole-abdominal CT performed for
detecting malignancy were normal. Cranial MRI, MR-angiog-
raphy and MR-venography were all within normal limits. No
pathological ﬁnding was found in consultation with otorhi-
nolaringology department conducted for dysphagia. Nasopha-
ryngeal MRI was considered as normal performed to exclude
malignancy in the nasopharynx due to involvement of the
cranial nerve VI. No lesion was found to explain restricted gaze
in orbital MRI investigation.
In the serum, antibody to acetylcholine was positive.
Decremental response (20%) was found on EMG investigation
of the subject.
Pridostigmine was started and its dose was gradually
increased to 120 mg/day three times daily. Intravenous
immune globulin was given for 5 days at dose of 0.4 mg/day.
IVIG treatment was started third day after the admission. His
complaints reduced four days later. Remarkable improvement
occurred at the end of day 7. On the neurological exam on the
7th post-IVIG treatment day it was observed that ptosis
recovered, gaze restriction regressed, gag reﬂex was positive,
swallowing improved, and speech of nasal character
regressed. Prednisolone at dose of 4 mg/day was added to
his treatment. The patient whose symptoms regressed and
bulbar signs disappeared is currently being followed in
neuromuscular out-patient clinic. Currently, the patient is
on treatment with 35 mg/day of corticosteroid and azathio-
pyrine and has no symptoms of MG or BD.
On the last neurological exam, it was observed that eye
closing was moderately weak and neurological exam was
normal in all other aspects, and that the patient had no oral
and genital ulcers and attacks of uveitis.
3. Discussion
Myasthenia gravis (MG) is an autoimmune neuromuscular
disease due to defect in neurotransmission developing through
formation of auto-antibodies to acetylcholine receptors, and
rarely to the post-synaptic molecule, i.e., muscle speciﬁc kinase
(MUSK). Eyelids and ocular muscles are usually ﬁrst involved. As
the condition advances, weakness spreads gradually from the
cranial to the extremity and axial muscles [8].
In regard to pathophysiology of MG, pathogenesis appears
to be due to B cells but in fact there is autoimmune response
depending on both T and B cells. T-cell dependent immuno-
logical attack occurs due to damage to the post-synaptic
membranes on the neuromuscular junction [9]. At the
neuromuscular junction, antibodies to acetylcholine (Ach)
receptor and complement components accumulate [9,10].
Receptor blockage, complement-mediated post-synaptic dam-
age, antibody-dependent receptor destruction, and receptor
internalization occur. Ultimately, number of the receptors
decrease and neuromuscular transmission weakens. T cells
involved in this process activate B cells and the pathogenesis is
primarily dependent on the B cells. T cell receptors, CD4, B7,
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B cells. Furthermore, B cells produce pro-inﬂammatory
cytokines for proliferation such as IL-6 and IFN-a [11–14].
Diagnosis of MG made based on the clinical ﬁndings
ﬂuctuating in day with oculobulbar manifestations dominat-
ing and response to the anti-cholinesterase agents. Presence of
anti-AChR or anti-MUSK antibodies, sequential nerve stimula-
tions and one-ﬁber electromyography are adjuvant diagnostic
investigations [15,16].
Behçet's disease (BD) has recently been recognized that the
condition is a multisystemic chronic inﬂammatory disease
presenting with remission and exacerbations associated with
some dermatological, vascular, neurological, locomotor, in-
testinal, urogenital, and cardiopulmonary symptoms in addi-
tion its classical triad [5,17]. Although recent studies have
suggested that the disease is an auto-inﬂammatory disease,
recent studies have demonstrated that BD is a pattern between
non-speciﬁc inﬂammation and auto-immune disorder [18].
Behçet's disease (BD) is a systemic vasculitis with unknown
etiology and pathogenesis. Only HLA-B51 is known to be
directly involved in its pathogenesis. Particularly, hypersensi-
tivity of T cells to many antigens is critical in the pathogenesis.
The cytokines and chemokines released from the APC and T
cells lead to hyperactivation of the neutrophils. Activated
neutrophils prime themselves as well as stimulate Th1 cells
through the cytokines they release. Interaction between APC,
Th1 lymphocytes and neutrophils is the basis of immune
response in BD [19]. The fact that cell-mediated cytotoxicity
demonstrated against oral mucosal antigens especially during
exacerbations of BD and immune complexes in the circulation
support the presence of immune reaction of both Th1 and Th2
types [17]. Activated monocytes in BH produce some pro-
inﬂammatory cytokines such as IL-1, IL-6, IL-8, TNF-a, and
granulocyte-macrophage colony stimulating factor (GM-CSF)
and these cytokines leading to tissue damage probably via
neutrophils contribute to leukocyte activation by interacting
with the endothelial cells. These pro-inﬂammatory cytokines
may activate non-pathogenic T- and B-cell responses. Partic-
ularly IL-8, known as major chemokine to attract and activate
leukocytes, is considered to play major role in pathogenesis of
the disease, and increased serum level of IL-8 has been
demonstrated in the patients with BD [17,18,20,21].
Both MG and BD may be associated with other autoimmune
diseases. Association of MG with thyrotoxicosis, mixed connec-
tive tissue disease, anti-cardiolipin antibodies, polymyositis has
been demonstrated with a frequency beyond being co-incidence
[22,23]. Association of MG has been reported with such
autoimmune diseases as neuromyelitisoptica, Morvan's syn-
drome, paraneoplastic syndromes [24], primary progressive
multiple sclerosis [25], Gulliain-Barré syndrome [26], multiple
sclerosis [27], Addison's disease [28], myasthenic syndrome [29],
anti-phospholipid antibody syndrome [30], myositis [31],
myotonic dystrophy [32], and Isaac's disease [33]. The disease
frequently accompanying Behçet's disease include ankylosing
spondylitis [34], IgA nephropathy [35], anti-phospholipid anti-
body syndrome [36], Vogi-Kayanagi-Harada syndrome [37],
Sjögren's syndrome [38], Takayasu disease [39], rheumatoid
arthritis, systemic lupus erythematosus [40].
T helper cells (TH), immunoglobulin-synthesizing B-cells,
and TNF-a which is one of the pro-inﬂammatory cytokines,and IL-6 are involved in common pathophysiology of both
diseases.
Association of MG and BD is very rare with no case has been
found in the literature except for one letter in 2004 [41].
Both BD and MG has been associated with autoimmune and
other diseases characterized by inﬂammation. Our case had
presented clinical course of MG starting after discontinuation
of his medications in another center for complications of
prednisolone and azathioprine that the patient had used for 17
years without interruption. It was observed that symptoms of
both MG and BD disappeared after starting corticosteroids.
Improvement in clinical ﬁndings of both diseases suggested us
a common pathophysiology.
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